✦ LIBER ✦

A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin

✍ Scribed by Satoshi Shakado; Yuko Akehi; Kaoru Yotsumoto; Atsushi Fukunaga; Shizuka Kuno; Takashi Tanaka; Kunitoshi Sakurai; Hideyuki Iwashita; Shuichi Ueda; Genryu Hirano; Keiji Yokoyama; Daisuke Morihara; Shinya Nishizawa; Masaharu Sakamoto; Akira Anan; Yasuaki Takeyama; Makoto Irie; Kaoru Iwata; Tetsuro Sohda; Shotaro Sakisaka

Book ID: 107650041
Publisher: Springer Japan
Year: 2011
Tongue: English
Weight: 393 KB
Volume: 4
Category: Article
ISSN: 1865-7257
DOI: 10.1007/s12328-011-0228-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The impact of combination therapy with p

The impact of combination therapy with peginterferon alfa-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients

✍ C. Hamer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Incidence of Neutropenia and Infections

Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin

✍ M. G. Antonini; S. Babudieri; I. Maida; C. Baiguera; B. Zanini; L. Fenu; G. Dett 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 271 KB

R1626 plus peginterferon Alfa-2a provide

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

✍ Paul J. Pockros; David Nelson; Eliot Godofsky; Maribel Rodriguez-Torres; Gregory 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 586 KB

R1626, a prodrug of the hepatitis C virus (HCV) RNA polymerase inhibitor R1479, showed time-dependent and dose-dependent reduction of HCV RNA levels in a previous study. The present study evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with peginterferon alfa-2a ؎

Mutation frequency of NS5A in patients v

Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy

✍ A. C. W. Jenke; S. Moser; V. Orth; M. Zilbauer; P. Gerner; S. Wirth 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

Interferon alfa-2b in combination with r

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics

✍ Regino P. González-Peralta; Deirdre A. Kelly; Barbara Haber; Jean Molleston; Kar 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 3 views

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh

Efficacy and tolerability of peginterfer

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

✍ T. Witthoeft; D. Hueppe; C. John; J. Goelz; R. Heyne; B. Moeller; G. Teuber; S. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB